الفهرس 
EPIDEMIOLOGYOnly 14 pages are availabe for public view
 |  | from | 192 |  |  |
| | | from | 192 | | |
Abstract
Ovarian cancer is the second most common gynecologic malignancy and the most common cause of mortality from gynecologic cancer. With the marginal effect of the current treatment protocols, a greater understanding of tumor biology and molecular pathways that mediate cancer progression and drug resistance has led to the development of various molecular-targeted therapies. Numerous targeted therapies are currently being evaluated in phase I/II and III studies. The most promising strategies developed so far are the Antiangiogenic approach and PARP inhibitors. Bevacizumab is a recombinant humanized monoclonal antibody directed against human VEGF. It has been shown (OCEANS Study) to improve PFS in patients with platinum-sensitive relapse, when given in conjunction with carboplatin and gemcitabine. Recently, bevacizumab treatment with concomitant standard (3-weekly carboplatin and paclitaxel) chemotherapy is used in patients with newly diagnosed ovarian cancer followed by maintenance bevacizumab for set periods of time after the completion of six cycles of chemotherapy. These studies showed an overall PFS advantage and improvement of OS in high risk group of patients. Oral Olaparib is a PARP inhibitor, and its effect on BRCA positive vs. BRCA wild-type patients in women with ovarian was studied. There was an improvement in the progression free survival in both mutated and wild type of BRCA patients. Role of PI3K/AKT/mTOR pathway and Src pathway targeting in ovarian cancer treatment is still in the early phases of clinical trials.